Evolent Health Inc (EVH) Expected to Post Quarterly Sales of $189.05 Million

Analysts forecast that Evolent Health Inc (NYSE:EVH) will report sales of $189.05 million for the current quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Evolent Health’s earnings, with estimates ranging from $187.67 million to $190.79 million. Evolent Health posted sales of $113.97 million during the same quarter last year, which would indicate a positive year over year growth rate of 65.9%. The firm is scheduled to report its next earnings report on Tuesday, February 26th.

On average, analysts expect that Evolent Health will report full year sales of $627.53 million for the current fiscal year, with estimates ranging from $621.70 million to $629.89 million. For the next fiscal year, analysts expect that the firm will report sales of $859.41 million, with estimates ranging from $836.40 million to $876.92 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Evolent Health.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, November 6th. The technology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.07. The business had revenue of $150.16 million for the quarter, compared to the consensus estimate of $142.94 million. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.18) EPS.

EVH has been the topic of several research analyst reports. Zacks Investment Research downgraded Evolent Health from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Evolent Health in a research note on Tuesday, August 7th. ValuEngine raised Evolent Health from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. KeyCorp lifted their price target on Evolent Health from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, August 20th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $37.00 price target on shares of Evolent Health in a research note on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company’s stock. Evolent Health presently has an average rating of “Buy” and a consensus price target of $31.73.

Evolent Health stock traded up $0.51 during mid-day trading on Monday, hitting $24.96. 800,963 shares of the company’s stock were exchanged, compared to its average volume of 885,055. The company has a market capitalization of $1.98 billion, a PE ratio of -35.66 and a beta of 1.50. Evolent Health has a fifty-two week low of $10.65 and a fifty-two week high of $29.05. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 0.12.

In other Evolent Health news, CEO Frank J. Williams sold 3,878 shares of Evolent Health stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $24.00, for a total value of $93,072.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Thomas Peterson III sold 30,000 shares of Evolent Health stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $25.00, for a total value of $750,000.00. The disclosure for this sale can be found here. Insiders sold a total of 163,592 shares of company stock worth $4,255,571 in the last three months. Company insiders own 4.82% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in EVH. NumerixS Investment Technologies Inc bought a new position in shares of Evolent Health in the 2nd quarter valued at about $105,000. DekaBank Deutsche Girozentrale grew its holdings in shares of Evolent Health by 235.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 6,205 shares of the technology company’s stock valued at $156,000 after acquiring an additional 4,355 shares in the last quarter. LPL Financial LLC bought a new position in shares of Evolent Health in the 1st quarter valued at about $184,000. Xact Kapitalforvaltning AB bought a new position in shares of Evolent Health in the 1st quarter valued at about $190,000. Finally, Public Employees Retirement Association of Colorado grew its holdings in shares of Evolent Health by 106.3% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 6,904 shares of the technology company’s stock valued at $196,000 after acquiring an additional 3,557 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Featured Story: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply